The integration of artificial intelligence (AI) in healthcare diagnostics is advancing rapidly, yet experts warn that it cannot address underlying issues in measurement reliability and data quality.
AI technologies are increasingly being utilized in various diagnostic tools, including biosensors and imaging systems, with regulatory bodies like the FDA actively reviewing their safety and effectiveness. However, the FDA has also recognized the operational risks associated with these AI systems, particularly in real-world clinical settings, where performance can drift and reliability may fluctuate over time.
Hyou-Arm Joung, CTO of Kompass Diagnostics, emphasizes that the effectiveness of AI in diagnostics is contingent upon the quality of the underlying measurement systems. He argues that without stable and well-structured data from these systems, AI can struggle to deliver meaningful insights. The variability introduced by biological samples, environmental conditions, and user interactions complicates the data landscape, which can hinder the robustness of AI models.
Moreover, the assumption that AI can compensate for weaknesses in diagnostic workflows is often misguided. Joung notes that while AI can enhance the interpretation of stable data, it may add complexity when the foundational systems lack reproducibility. This complexity can lead to challenges in regulatory compliance and quality management, ultimately affecting patient outcomes.
As the healthcare industry continues to invest in AI diagnostics, the focus should shift towards developing reliable diagnostic infrastructures. Successful AI integration will depend on creating robust systems that ensure consistent data quality, rather than merely layering AI onto existing, unstable platforms.